ROS1-Rearranged NSCLC

(4:55)

TRIDENT-1: repotrectinib in ROS1-positive NSCLC

(8:16)

What is a ROS1 mutation in lung cancer?

(40)

How do doctors treat lung cancer with ROS1 mutations?

(2:47)

Dr. Drilon on Entrectinib in Patients With ROS1-Positive NSCLC

(2:12)

Best New Lung Cancer Treatments for ROS1 Mutation

(1:3)

ROS-1 Rearrangements: What Are They?

(1:53)

Advice for ROS1 Patients: John

(46)

Understanding NSCLC Treatments for Less Common Mutations: ALK, BRAF, ROS1, HER2, MET

(5:41)

Emerging ALK/ROS1 TKIs for NSCLC

(4:49)

Managing ROS1 fusion-positive NSCLC in Europe and the USA | Panel discussion

(37:34)

The Evolution of ALK/ROS1-Targeted Therapy in NSCLC

(4:5)

ROS1-Positive Lung Cancer and Brain Tumors

(1:56)

Upfront treatment of ROS1-rearranged NSCLC

(2:37)

Dr. Riess on ROS1 Fusions in Lung Cancer

(1:51)

Treatment Considerations in ALK/ROS-1–Rearranged NSCLC

(3:55)

ROS1 Rearrangements in mNSCLC

(3:15)

Dr. Camidge on Crizotinib as a ROS1 Inhibitor in NSCLC

(1:9)

ALK/ROS1-Rearranged NSCLC: Approaching Therapy

(3:31)

Dr. Feliciano on ROS1-Targeted Therapy in NSCLC

(1:45)